Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**EpicaPatch** is an investigational epicardial regenerative cardiac therapy developed by **Regencor** for use during surgical coronary revascularization, particularly coronary artery bypass grafting after myocardial infarction. It consists of a **compressed bioabsorbable collagen matrix** loaded with **human follistatin-like 1 protein** in a hypoglycosylated or recombinant form and is fixed onto the epicardial surface over the infarct zone at the time of surgery. The product is designed as a **sustained-release protein biologic patch** intended to promote myocardial regeneration, improve contractile function, reduce scar burden, and prevent progression to heart failure after ischemic injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EpicaPatch.